SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings ($CLIK) is trending due to significant revenue growth and its micro-float status, drawing attention from traders seeking potential for substantial gains. Community members highlight the stock's small float and revenue increase, anticipating a potential breakout. Some are attributing the recent price action to a bot alert and solid news, while also comparing it to other low-float runners.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending due to community discussion around an Adweek article and its potential impact from Amazon's competitive moves in the DSP space, with many suggesting the article was misleading and reporting it to the SEC. Community members are debating the long-term value of TTD amidst competition from larger tech companies and potential market manipulation. Despite concerns, some bulls remain confident in the stock's potential, citing strong fundamentals and potential for a rebound.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as retail traders discuss a potential short squeeze, with community members pointing to high borrowing costs for short sellers and a limited float. Talk centers around a large buy order that could trigger significant upward movement. Some traders are comfortable holding shares while others are looking for an entry point or taking profits.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as the community discusses the FDA approval of their leukemia drug, Revuforj, while also noting warnings of potentially serious side effects, including differentiation syndrome and heart rhythm issues. Some see this as a buying opportunity, anticipating a future rebound, while others are concerned about the black box warning impacting physician adoption and uptake. There is also discussion of a potential buyout.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

PMI is trending due to after-hours price action and community speculation about a potential short squeeze or upcoming news, despite the company stating they are unaware of any material changes. Traders are actively discussing potential price movements and the possibility of dilution, creating volatility. The stock's movement is also attracting attention as a potential play in the medical sector.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to an FDA investigation into increased reports of allergic reactions following infusions of specific lots of Immune Globulin Intravenous (IGIV), including two ADMA product lots, causing community concern and triggering a selloff. While some investors express fear and accuse manipulation, others see a buying opportunity, citing the company's fundamentals and potential pre-earnings run. The community is also discussing potential takeover bids and revenue targets.

Meet DragonWifBeard: The world's first AI-powered pet dragon!  More Than Just Scales: DragonWifBeard is a real-life bearded dragon revolutionizing the pet experience. He's not just any reptile – he's equipped with cutting-edge Eliza AI agent, giving him a unique personality and the ability to interact with his environment in unprecedented ways. The Future of Companionship: This groundbreaking project merges the love for pets with the limitless possibilities of AI. Witness the dawn of a new era in companionship with DragonWithBeard.

DragonWifBeard

DragonWifBeard ($DWB) is trending as community members highlight its potential for 'fire' and 'profits,' inviting others to join. Conversations frequently mention Solana ($SOL) and other popular cryptos, with users emphasizing the token's availability on Phantom Wallet. The discussions suggest a focus on community growth and capitalizing on the token's momentum.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

GNTA is experiencing significant volatility, with community members actively discussing a large pre-market surge following news of a strategic partnership. The conversation includes speculation about a short squeeze, potential for further gains, and caution due to the stock's history of volatile price action and possible pump and dump schemes. Some traders are taking profits while others are holding in anticipation of after-hours movement.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp ($USAU) is trending as investors discuss its potential spin-off of the Keystone project and debt financing options expected by year-end. Bullish sentiment is fueled by rising gold prices and upcoming Russell index inclusion, while some community members express concerns about management experience and potential dilution. Discussions also involve price targets and speculation about institutional accumulation.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending as community members debate its potential, with some expressing frustration over a lack of sustained gains and questioning the team's communication, while others remain optimistic about its long-term prospects in the decentralized physical infrastructure (DePIN) space and speculate on upcoming news or partnerships. Discussions also revolve around staking rewards and the utility of the XYO token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Paris, France-based Abivax SA (ABVX) spiked by over 400% in Wednesday's early premarket session following a positive late-stage readout from the clinical-stage biotech.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax stock</a> improved further into the ‘extremely bullish’ territory (98/100), with the message volume score spiking to a near-perfect “99,” suggesting ‘extremely high’ retail chatter.<figure class="image"><img style="aspect-ratio:626/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_4_32_00_AM_png_77d276515d.webp" alt="Screenshot 2025-07-23 at 4.32.00 AM.png" width="626" height="56"><figcaption>ABVX sentiment and message volume as of 4:30 a.m., July 23 | source: Stocktwits</figcaption></figure>The Abivax stock stream on the platform saw a nearly 260% increase in watcher count over the 24 hours leading up to late Tuesday. The 24-hour message volume change was 3,900%.The stock was among the top five trending tickers on Stocktwits early Wednesday.The frenzied retail activity followed the small-cap biotech's announcement of positive topline results from two Phase 3 studies evaluating its obefazimod in adult patients with moderately to severely active ulcerative colitis (UC).Abivax evaluated a 50 mg once-daily oral dose of obefazimod, its lead candidate, in studies dubbed ABTECT 1 and ABTECT 2. The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.It also met all key secondary endpoints, demonstrating “highly statistically significant and clinically meaningful benefits.”The company said an ABTECT Maintenance trial is ongoing, with topline results expected in the second quarter of 2026. It added that out of the 1,275 patients randomized in the induction trials, 678 achieved a clinical response and were enrolled in part 1 of the maintenance trial.Abivax CEO Marc de Garidel said, “The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC.”Contingent upon the 44-week maintenance trial producing successful results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Abiva engages in the development of therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.A bullish Stocktwits watcher flagged a potential move toward the $60-$80 level on Wednesday.<stembedurl>https://stocktwits.com/europetradefuture/message/622045234</stembedurl>Another user, who identified themselves as a UC patient, said, “The addressable market is huge and physicians are always looking for another treatment option aside from TNFs, JAKs, interleukins, etc — some of the biggest blockbuster drugs currently treat UC/Crohns.”<stembedurl>https://stocktwits.com/Jblack500/message/622027325</stembedurl>Abivax stock is up over 36.5% for the year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/south-korean-feels-the-heat-after-japan-inks-trump-trade-deal-officials-in-dc/ch8wK2GR5M7">South Korea Feels The Heat After Japan Inks Trump Trade Deal — Officials In DC To Salvage Terms Before August Deadline</a>

Artwork based on an endoscopic image of the colon affected by ulcerative colitis (Photo Courtesy of Juan Gartner via Getty Images)

Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results  — Retail Buzz Builds Around Blockbuster Potential

The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.

Equity

US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug

Investing.com-- U.S.-listed shares of French biotech firm  Abivax SA  (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.

Kepler Capital  Reaffirms Their Buy Rating on Abivax SA (0RA9)

In a report released on July 16, Justine Telliez from Kepler Capital maintained a Buy rating on Abivax SA (0RA9 Research Report), with a price ta...

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the...

Abivax reports 2023 financial results and operational update

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR...

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics...

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET Abivax SA (Euronext Paris and Nasdaq: ABVX) ( Abivax or the Company ), a...

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December...

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024...

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$90.76
Prev Close	$90.47
Open	$91.91
Dividend Yield	0.00%
50-Day Moving Average	$84.11
Beta	0.83
Avg. Volume	1.04M
PE Ratio	-29.92

52-Week High	$98.64
52-Week Low	$4.77
Market Capitalization	$6.17B
EPS (Annual)	-$3.02
Price to Book	-101.32
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABVX News

ABVXAbivax - ADR